'Arcus Biosciences Set to Join S&P SmallCap 600,' Replacing Investors Bancorp -S&P Dow Jones Indices
$CFG
$ISBC
$RCUS
Major Banks
Finance
Savings Institutions
Finance
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 3/9/2026 | $65.00 | Neutral → Outperform | Robert W. Baird | |
| 2/12/2026 | $23.00 | Overweight → Equal Weight | Wells Fargo | |
| 1/13/2026 | $28.00 | Neutral → Buy | Goldman | |
| 1/8/2026 | $20.00 | Overweight → Equal-Weight | Morgan Stanley | |
| 1/7/2026 | $66.00 | Strong Buy → Outperform | Raymond James | |
| 1/5/2026 | $77.00 | Equal Weight → Overweight | Barclays | |
| 12/11/2025 | $60.00 | Outperform → Neutral | Robert W. Baird | |
| 10/9/2025 | $65.00 | Neutral → Buy | BofA Securities |
Robert W. Baird upgraded Citizens Financial Group from Neutral to Outperform and set a new price target of $65.00
Wells Fargo downgraded Arcus Biosciences from Overweight to Equal Weight and set a new price target of $23.00
Goldman upgraded Arcus Biosciences from Neutral to Buy and set a new price target of $28.00
4 - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Issuer)
4 - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Issuer)
4 - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Issuer)
As previously announced, Citizens Financial Group, Inc. (NYSE:CFG) will report its first quarter 2026 earnings on April 16, 2026. The news release and supplemental materials will be available at http://investor.citizensbank.com. CFG management will host a live conference call that morning with details as follows: Time: 9:00 am (ET) Dial-in: To ask a question on the call, individuals may call in by dialing 800-369-1703, conference ID 1679767 For the listen only line, individuals may call in by dialing 800-475-8432, conference ID 7623330 Webcast/Presentation: The live webcast will be available at http://investor.citizensbank.com under Events & Pre
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 17,050 shares of the Company's common stock at an exercise price per share of $23.43, which was the closing price on March 9, 2026, and restricted stock units to acquire a total of 8,550 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Co
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2026 Date: Monday, March 9th, 2026 Location: Miami, FL Format: Fireside chat & 1x1 meetings Time: 11:20 a.m. ET Barclays 28th Annual Global Healthcare Conference Date: Tuesday, March 10th, 2026 Location: Miami Beach, FL Format: 1x1 meetings A live webcast of the fireside chat will be available by visiting the "Investors & M
DEFA14A - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Filer)
DEF 14A - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Filer)
S-3ASR - Arcus Biosciences, Inc. (0001724521) (Filer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
Deal strengthens coverage of Downstream Energy & Convenience Retail sector Citizens Financial Group, Inc. (NYSE:CFG) today announced a definitive agreement to purchase substantially all the assets of Matrix Capital Markets Group, Inc., a market-leading advisory firm in the Downstream Energy & Convenience Retail sector, with additional expertise and proven success in the Automotive Aftermarket and Outdoor Recreation and Marine sectors. This transaction further strengthens Citizens' sector-focused advisory capabilities. Founded in 1988, Matrix has its headquarters in Richmond, VA, and a second office in Baltimore, MD, as well as bankers based in Cleveland and Atlanta, and serves clients a
Citizens Financial Group, Inc. (NYSE:CFG) today announced the appointment of Aunoy Banerjee as Executive Vice President and Chief Financial Officer. He will serve on the company's Executive Committee and report to Chairman and CEO Bruce Van Saun. Banerjee joins Citizens from Barclays, where he currently serves as CFO of Barclays Bank PLC, leading a large, global, multifunctional team supporting multiple lines of business including U.S. Consumer, Global Corporate and Investment Banking, and Private Bank and Wealth Management. Banerjee will join Citizens on October 24. As previously announced, current CFO John Woods will depart the bank on August 15. Chris Emerson, EVP and Head of Corporate
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock at an exercise price per share of $12.45, which was the closing price on February 10, 2025, and restricted stock units to acquire a total of 75,193 shares of the Company's common stock. In addition to the awards to Dr. Markus, the Co
As previously announced, Citizens Financial Group, Inc. (NYSE:CFG) will report its first quarter 2026 earnings on April 16, 2026. The news release and supplemental materials will be available at http://investor.citizensbank.com. CFG management will host a live conference call that morning with details as follows: Time: 9:00 am (ET) Dial-in: To ask a question on the call, individuals may call in by dialing 800-369-1703, conference ID 1679767 For the listen only line, individuals may call in by dialing 800-475-8432, conference ID 7623330 Webcast/Presentation: The live webcast will be available at http://investor.citizensbank.com under Events & Pre
Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD) cohort At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing Phase 3 PEAK-1 study, Arcus plans to initiate a Phase 3 study in the first-line (1L) metastatic setting evaluating casdatifan in a tyrosine kinase inhibitor (TKI)-free combination by the end of 2026 With $1.0 billion in cash, cash equivalents and marketable securities at year-
Citizens Financial Group, Inc. (NYSE:CFG) announced that its board of directors has declared the following dividends on its preferred stock payable on April 6, 2026, to preferred shareholders of record at the close of business on March 20, 2026: a quarterly cash dividend of $17.28595 per share on CFG's 6.000% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series B (CUSIP No. 174610AP0); a quarterly cash dividend of $17.67095 per share on CFG's 6.375% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series C (CUSIP No. 174610AQ8); a quarterly cash dividend of $12.50 per share ($0.3125 per each depositary share, each representing a 1/40th interest in
SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Subject)
SC 13G/A - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Subject)